Vir Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Vir Biotechnology has a total shareholder equity of $1.5B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.8B and $246.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.15b |
| Equity | US$1.55b |
| Total liabilities | US$246.61m |
| Total assets | US$1.79b |
Recent financial health updates
No updates
Recent updates
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05
Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
Oct 12Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B
Oct 04Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus
Sep 22Vir Biotechnology falls 15% on Q2 revenue miss impacted by ~$400M for potential write-offs
Aug 09Vir: Biotechnology's Best Near-Term Capital Gain Prospect
Jul 27Vir Biotechnology announces transition of chief scientific officer
Jul 14Financial Position Analysis
Short Term Liabilities: VIR's short term assets ($1.2B) exceed its short term liabilities ($94.1M).
Long Term Liabilities: VIR's short term assets ($1.2B) exceed its long term liabilities ($152.5M).
Debt to Equity History and Analysis
Debt Level: VIR is debt free.
Reducing Debt: VIR has no debt compared to 5 years ago when its debt to equity ratio was 7.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VIR has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 10.8% each year.